Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanna Joensen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Brain and Behavior|February 11, 2026
Diagnoses of Multiple Sclerosis and Related Disorders and Disease-Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health RegistriesHanna Joensen, Elisabeth Framke, Luigi Pontieri, et al.
Brain and Behavior|October 31, 2020
The Danish Multiple Sclerosis RegistryMelinda Magyari, Hanna Joensen, Bjarne Laursen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 13, 2022
Changes in prognosis of the Danish multiple sclerosis population over timeMelinda Magyari, Hanna Joensen, Tine Iskov Kopp, et al.
Multiple Sclerosis and Related Disorders|February 12, 2021
Age and sex as determinants of treatment decisions in patients with relapsing-remitting MSPer Soelberg Sorensen, Tine Iskov Kopp, Hanna Joensen, et al.
Multiple Sclerosis and Related Disorders|May 25, 2026
A nationwide temporal analysis of socioeconomic outcomes in Denmark's multiple sclerosis populationElisabeth Framke, Lene von Kappelgaard, Frederik Elberling, et al.
JAMA Neurology|August 16, 2021
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National StrategiesTim Spelman, Melinda Magyari, Fredrik Piehl, et al.
Multiple Sclerosis and Related Disorders|January 9, 2023
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide studyPer Soelberg Sorensen, Luigi Pontieri, Hanna Joensen, et al.
Multiple Sclerosis and Related Disorders|April 14, 2023
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-upMathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, et al.
European Journal of Neurology|October 13, 2021
Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort studyLuigi Pontieri, Morten Blinkenberg, Stephan Bramow, et al.
Therapeutic Advances in Neurological Disorders|September 29, 2023
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard Nicholas, Jeff Rodgers, James Witts, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Brain and Behavior|February 11, 2026
Diagnoses of Multiple Sclerosis and Related Disorders and Disease-Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health RegistriesHanna Joensen, Elisabeth Framke, Luigi Pontieri, et al.
Brain and Behavior|October 31, 2020
The Danish Multiple Sclerosis RegistryMelinda Magyari, Hanna Joensen, Bjarne Laursen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 13, 2022
Changes in prognosis of the Danish multiple sclerosis population over timeMelinda Magyari, Hanna Joensen, Tine Iskov Kopp, et al.
Multiple Sclerosis and Related Disorders|February 12, 2021
Age and sex as determinants of treatment decisions in patients with relapsing-remitting MSPer Soelberg Sorensen, Tine Iskov Kopp, Hanna Joensen, et al.
Multiple Sclerosis and Related Disorders|May 25, 2026
A nationwide temporal analysis of socioeconomic outcomes in Denmark's multiple sclerosis populationElisabeth Framke, Lene von Kappelgaard, Frederik Elberling, et al.
JAMA Neurology|August 16, 2021
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National StrategiesTim Spelman, Melinda Magyari, Fredrik Piehl, et al.
Multiple Sclerosis and Related Disorders|January 9, 2023
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide studyPer Soelberg Sorensen, Luigi Pontieri, Hanna Joensen, et al.
Multiple Sclerosis and Related Disorders|April 14, 2023
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-upMathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, et al.
European Journal of Neurology|October 13, 2021
Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort studyLuigi Pontieri, Morten Blinkenberg, Stephan Bramow, et al.
Therapeutic Advances in Neurological Disorders|September 29, 2023
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard Nicholas, Jeff Rodgers, James Witts, et al.
Pageof 2